Halozyme Therapeutics, Inc. vs. Twist Bioscience Corporation Common Stock
HALO
Halozyme Therapeutics, Inc.
$108.17 +1.93%
VS TWSTTwist Bioscience Corporation Common Stock
$145.59 +6.79%
Halozyme Therapeutics, Inc. (HALO) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| HALO | TWST | |
|---|---|---|
| Market Cap | $12.21 billion | $8.55 billion |
| Revenue (TTM) | $1.66 billion | $431.80 million |
| Net Income (TTM) | $413.60 million | $-136,717,000 |
HALO leads on 3 of 3 size & scale factors.
Valuation
| HALO | TWST | |
|---|---|---|
| P/E Ratio | 31.63 | — |
| Price / Book | 85.09 | 19.18 |
| Price / Sales | 7.34 | 19.80 |
HALO and TWST split the valuation factors evenly.
Profitability
| HALO | TWST | |
|---|---|---|
| Net Margin | 24.86% | -31.66% |
| Return on Equity | 288.13% | -30.67% |
HALO leads on 2 of 2 profitability factors.
Risk & Sentiment
| HALO | TWST | |
|---|---|---|
| Short Interest | 9.79% | 0.08% |
TWST leads on 1 of 1 risk & sentiment factors.
Dig deeper: HALO overview, HALO financials, TWST overview, TWST financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.